US drugmaker Eli Lilly – still waiting for an FDA decision on one non-opioid pain drug – has just added another to its pipeline via a licensing agreement with Japan’s Asahi Kasei worth up t
SMi Group reports: Pain Therapeutics conference is a one-stop shop to discover all of the cutting-edge news, updates and case-studies regarding developments in the field of analgesic medicine
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh